Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

• Crossref
• PubMed
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.10.3322/caac.2155130620402)| false
• Search Google Scholar
• Export Citation

Llovet JM, Ricci S, Mazzaferro V, et al.. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.

• Crossref
• PubMed
Llovet JM, Ricci S, Mazzaferro V, . SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.10.1056/NEJMoa070885718650514)| false
• Search Google Scholar
• Export Citation

Benson AB III, D’Angelica MI, Abbott DE, et al.. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2019. Accessed May 9, 2019. To view the most recent version, visit NCCN.org.

Gyawali B, Kesselheim AS. US Food and Drug Administration approval of new drugs based on noninferiority trials in oncology: a dangerous precedent? JAMA Oncol 2019;5:607–608.

• Crossref
Gyawali B, Kesselheim AS. US Food and Drug Administration approval of new drugs based on noninferiority trials in oncology: a dangerous precedent? JAMA Oncol 2019;5:607–608.10.1001/jamaoncol.2019.0093)| false
• Search Google Scholar
• Export Citation

Gyawali B, Prasad V. Health policy: me-too drugs with limited benefits: the tale of regorafenib for HCC. Nat Rev Clin Oncol 2017;14:653–654.

• Crossref
• PubMed
Gyawali B, Prasad V. Health policy: me-too drugs with limited benefits: the tale of regorafenib for HCC. Nat Rev Clin Oncol 2017;14:653–654.10.1038/nrclinonc.2017.10028719584)| false
• Search Google Scholar
• Export Citation

Gormley NJ, Pazdur R. Immunotherapy combinations in multiple myeloma—known unknowns. N Engl J Med 2018;379:1791–1795.

• Crossref
• PubMed
Gormley NJ, Pazdur R. Immunotherapy combinations in multiple myeloma—known unknowns. N Engl J Med 2018;379:1791–1795.3040393510.1056/NEJMp1803602)| false
• Search Google Scholar
• Export Citation

Sanoff HK, Chang Y, Lund JL, et al.. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 2016;21:1113–1120.

• Crossref
• PubMed
Sanoff HK, Chang Y, Lund JL, . Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 2016;21:1113–1120.2718561510.1634/theoncologist.2015-0478)| false
• Search Google Scholar
• Export Citation

Soto-Perez-de-Celis E, Aguiar PN Jr, Cordón M, et al.. Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw 2019;17:669–675.

• Crossref
• PubMed
Soto-Perez-de-Celis E, Aguiar PN Jr, Cordón M, . Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw 2019;17:669–675.10.6004/jnccn.2018.727531200357)| false
• Search Google Scholar
• Export Citation

Goldstein DA, Chen Q, Ayer T, et al.. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 2015;1:1293–1300.

• Crossref
• PubMed
Goldstein DA, Chen Q, Ayer T, . Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 2015;1:1293–1300.10.1001/jamaoncol.2015.331626313558)| false
• Search Google Scholar
• Export Citation

Ettinger DS, Wood DE, Aggarwal C, et al.. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4.2019. Accessed May 9, 2019. To view the most recent version, visit NCCN.org.